U.S. Lidocaine Patch Market
U.S. Lidocaine Patches Market size was valued at USD 560.7 million in 2024 and is projected to reach a valuation of USD 963 million by the end of 2034, rising at a CAGR of 5.5% during the forecast period, i.e., 2025-2034. In 2025, the industry size of U.S. lidocaine patches is assessed at USD 591.2 million.
The U.S. lidocaine patches market is witnessing expansion due to an aging population and a growing demand for non-opioid pain management solutions. This aging population is indicative of the growing demand for targeted pain therapies like lidocaine patches. For instance, in February 2024, Scilex Holding Company announced that its flagship product, ZTlido, has more than one million users. Such advancements reinforce the growing adoption of lidocaine patches for safe, localized pain relief. Government healthcare initiatives on palliative care and pain management also further drive market growth.
The United States lidocaine patches market is evolving with innovative product developments that are offering superior pain relief options to the consumer. Hisamitsu America introduced the Salonpas Pain Relieving FLEX Patch Lidocaine 4% in June 2022, characterized by superior flexibility for improved wearability. These developments are a response to the increasing burden of chronic diseases, including arthritis and cancer, for which palliative care solutions are imperative. Moreover, government-supported programs aimed at substituting opioids with other painkillers reflect a general approach to the problem of opioid addiction and, thus, accelerate the demand for lidocaine patches in the U.S.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2034 |
|
CAGR |
5.5% |
|
Base Year Market Size (2024) |
USD 560.7 million |
|
Forecast Year Market Size (2034) |
USD 963 million |
|
Regional Scope |
|
Type (Prescription Medicines, OTC Medicines)
Prescription medicines segment is anticipated to capture around 72.2% U.S. lidocaine patches market share by the end of 2034. This dominance is driven by the effectiveness of prescription-grade patches in managing moderate to severe pain, such as post-surgical pain and chronic neuropathy. These patches are preferred in medical settings for their reliable and clinically validated performance. The segment benefits from rigorous research and development efforts to ensure safety and efficacy standards. With healthcare providers increasingly recommending non-opioid alternatives, the prescription medicines segment remains a cornerstone of the market.
End user (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers)
By the end of 2034, hospital pharmacies segment is set to hold over 41.7% U.S. lidocaine patches market share, due to the important distribution role prescription-grade lidocaine patches play in facilities. The hospitals also ensure timely access to effective pain management solutions among patients recovering from surgeries or dealing with chronic conditions. For example, FFF Enterprises partnered with Sintetica US in April 2023 to distribute Lidocaine Hydrochloride Injection, thereby underlining the importance of hospital-centric distribution networks. While this partnership is predominantly focused on injectable formulations, it underlines the potential synergies in expanding the lidocaine offering, including patches. Hospital pharmacies form the most crucial end user in meeting the growing demand for lidocaine patches throughout the U.S.
Our in-depth analysis of the market includes the following segments:
|
Type |
|
|
End user |
|
Southeast Market Analysis
Southeast U.S. lidocaine patches market size is expected to reach USD 247.6 million by 2034, due to growing healthcare infrastructure coupled with an increase in the population aged 65 years or more. Several states of this region are investing in facilities regarding palliative care because of the prevalence of disorders related to chronic pain. Awareness for solutions connected with the management of pain without the help of opioids is being created through various campaigns, which is further escalating the use of lidocaine patches. The Southeast U.S. lidocaine patches market is anticipated to be lucrative due to healthcare providers advocating pain relief methods in localized forms.
Midwest U.S. Lidocaine Patches Market Statistics
Midwest United States lidocaine patches market is predicted to register growth of around 5.8% till 2034. As a matter of fact, significant awareness of localized pain management solution options, along with aging populations in the region, could also propel market growth in this segment. Hisamitsu America announced the introduction of its advanced thin and flexible technology-based Salonpas Pain Relieving FLEX Patch Lidocaine 4% in June 2022. The innovation aims at the preference of consumers towards OTC solutions, providing comfort associated with effectiveness. The launch reflects the growing demand for user-friendly lidocaine patches that are designed to meet the diverse needs of consumers in the Midwest.
The U.S. lidocaine patches market is highly competitive, comprising key players such as Amneal Pharmaceuticals LLC, Hisamitsu America, Inc., Scilex Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., and YARAL Pharma Inc., which, through their contributions, drive the growth of the segment. Major players in this market invest significantly in research and development to bring about new and innovative products to meet the growing demand for effective and non-opioid pain management solutions. Their strategies have been the development of portfolios to address a range of pain conditions and building robust distribution networks. With the growing demand for localized pain relief options, these companies are further solidifying their market positions through strategic partnerships, acquisitions, and directed marketing efforts.
In June 2023, Huons Co. obtained FDA approval for the 2% lidocaine injection, a significant achievement in its development in the U.S. lidocaine patches market. While this regulatory success is based on injectable solutions, Huons demonstrates the potential for diversification into lidocaine patch offerings. Such approval indicates that the company meets the highest U.S. standards and positions it as competitive in the field of localized pain management. Furthermore, this points to a wider trend that highlights global companies are beginning to see the U.S. as a prime target market for advanced pain relief solutions.
Here are some leading companies in the U.S. lidocaine patches market:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?